Abstract
Background: Long-term glucocorticoid therapy has been suggested to improve airway and airway vascular smooth muscle responsiveness to inhaled β2-agonists in patients with asthma. Objective: We sought to assess whether a single dose of an inhaled glucocorticoid acutely potentiates β2-adrenergic airway and airway vascular smooth muscle reactivity in asthma. Methods: In 10 asthmatic and 10 healthy subjects, airway blood flow and FEV1 were measured before and 30 minutes after fluticasone or placebo inhalation and 15 minutes after the subsequent inhalation of racemic albuterol (0.6 mg or 1.25 mg) or (R)-albuterol (0.3 mg or 0.6 mg). Results: In healthy subjects all albuterol formulations increased airway blood flow equally after placebo or fluticasone pretreatment. In asthmatic subjects airway blood flow response was blunted after placebo and acutely restored after fluticasone pretreatment. Fluticasone pretreatment did not increase FEV1 responses to any albuterol formulation, except 0.6 mg racemic albuterol. Conclusion: A single dose of an inhaled glucocorticoid restores β2-adrenergic airway vasodilator responses in patients with mild asthma. The mechanism of this rapid glucocorticoid effect remains to be clarified.
| Original language | English |
|---|---|
| Pages (from-to) | 700-704 |
| Number of pages | 5 |
| Journal | Journal of Allergy and Clinical Immunology |
| Volume | 121 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 1 2008 |
Fingerprint
Keywords
- β-agonists
- airway blood flow
- albuterol
- Asthma
- corticosteroids
- fluticasone
- levalbuterol
- nongenomic action
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Cite this
Rapid corticosteroid effect on β2-adrenergic airway and airway vascular reactivity in patients with mild asthma. / Mendes, Eliana; Horvath, Gabor; Campos, Michael A; Wanner, Adam.
In: Journal of Allergy and Clinical Immunology, Vol. 121, No. 3, 01.03.2008, p. 700-704.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Rapid corticosteroid effect on β2-adrenergic airway and airway vascular reactivity in patients with mild asthma
AU - Mendes, Eliana
AU - Horvath, Gabor
AU - Campos, Michael A
AU - Wanner, Adam
PY - 2008/3/1
Y1 - 2008/3/1
N2 - Background: Long-term glucocorticoid therapy has been suggested to improve airway and airway vascular smooth muscle responsiveness to inhaled β2-agonists in patients with asthma. Objective: We sought to assess whether a single dose of an inhaled glucocorticoid acutely potentiates β2-adrenergic airway and airway vascular smooth muscle reactivity in asthma. Methods: In 10 asthmatic and 10 healthy subjects, airway blood flow and FEV1 were measured before and 30 minutes after fluticasone or placebo inhalation and 15 minutes after the subsequent inhalation of racemic albuterol (0.6 mg or 1.25 mg) or (R)-albuterol (0.3 mg or 0.6 mg). Results: In healthy subjects all albuterol formulations increased airway blood flow equally after placebo or fluticasone pretreatment. In asthmatic subjects airway blood flow response was blunted after placebo and acutely restored after fluticasone pretreatment. Fluticasone pretreatment did not increase FEV1 responses to any albuterol formulation, except 0.6 mg racemic albuterol. Conclusion: A single dose of an inhaled glucocorticoid restores β2-adrenergic airway vasodilator responses in patients with mild asthma. The mechanism of this rapid glucocorticoid effect remains to be clarified.
AB - Background: Long-term glucocorticoid therapy has been suggested to improve airway and airway vascular smooth muscle responsiveness to inhaled β2-agonists in patients with asthma. Objective: We sought to assess whether a single dose of an inhaled glucocorticoid acutely potentiates β2-adrenergic airway and airway vascular smooth muscle reactivity in asthma. Methods: In 10 asthmatic and 10 healthy subjects, airway blood flow and FEV1 were measured before and 30 minutes after fluticasone or placebo inhalation and 15 minutes after the subsequent inhalation of racemic albuterol (0.6 mg or 1.25 mg) or (R)-albuterol (0.3 mg or 0.6 mg). Results: In healthy subjects all albuterol formulations increased airway blood flow equally after placebo or fluticasone pretreatment. In asthmatic subjects airway blood flow response was blunted after placebo and acutely restored after fluticasone pretreatment. Fluticasone pretreatment did not increase FEV1 responses to any albuterol formulation, except 0.6 mg racemic albuterol. Conclusion: A single dose of an inhaled glucocorticoid restores β2-adrenergic airway vasodilator responses in patients with mild asthma. The mechanism of this rapid glucocorticoid effect remains to be clarified.
KW - β-agonists
KW - airway blood flow
KW - albuterol
KW - Asthma
KW - corticosteroids
KW - fluticasone
KW - levalbuterol
KW - nongenomic action
UR - http://www.scopus.com/inward/record.url?scp=40049105909&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=40049105909&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2007.10.038
DO - 10.1016/j.jaci.2007.10.038
M3 - Article
C2 - 18086493
AN - SCOPUS:40049105909
VL - 121
SP - 700
EP - 704
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
SN - 0091-6749
IS - 3
ER -